27 min listen
Venous Thromboembolism Risk Markers and Discontinuing Combined Hormonal Contraceptives
FromThe Hematologist
Venous Thromboembolism Risk Markers and Discontinuing Combined Hormonal Contraceptives
FromThe Hematologist
ratings:
Length:
26 minutes
Released:
May 7, 2024
Format:
Podcast episode
Description
In this episode, Contributing Editor Samuel Wilson, MD, an assistant professor of hematology at the University of North Carolina, Chapel Hill, talks with Marc Blondon, MD, an attending physician in the division of angiology and hemostasis with the Geneva University Hospitals in Switzerland. They talk about a paper co-authored by Dr. Blondon titled, “Longitudinal profile of estrogen-related thrombotic biomarkers after cessation of combined hormonal contraceptives.” Dr. Wilson wrote about the study in a recent issue of The Hematologist.
Released:
May 7, 2024
Format:
Podcast episode
Titles in the series (100)
BCL-2 Is an Effective Target in Chronic Lymphocytic Leukemia: In her Diffusion article from the May/June issue of The Hematologist, Dr. Ann LaCasce (Dana-Farber Cancer Institute) discusses the use of the recently FDA-approved drug venetoclax for the treatment of patients with chronic lymphocytic leukemia (CLL) or sm by The Hematologist